Lab-on-a-Chip Immunoassay for Prediction of Severe COVID-19 Disease

Harald Peter; Emily Mattig; Paul C Guest; Frank F Bier

doi:10.1007/978-1-0716-2395-4_17

Lab-on-a-Chip Immunoassay for Prediction of Severe COVID-19 Disease

Methods Mol Biol. 2022:2511:235-244. doi: 10.1007/978-1-0716-2395-4_17.

Authors

Harald Peter¹, Emily Mattig², Paul C Guest³, Frank F Bier^{4

5}

Affiliations

¹ Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam, Germany. Harald.Peter@izi-bb.fraunhofer.de.
² Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam, Germany.
³ Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
⁴ Institute of Biochemistry and Biology, University of Potsdam, Potsdam, Germany.
⁵ Institute of Molecular Diagnostics and Bioanalysis (IMDB gGmbH), Berlin, Germany.

PMID: 35838964
DOI: 10.1007/978-1-0716-2395-4_17

Abstract

Most people infected by the SARS-CoV-2 virus which causes COVID-19 disease experience mild or no symptoms. Severe forms of the disease are often marked by a hyper-inflammatory response known as a cytokine storm. Thus, biomarker tests which can identify these patients and place them on the appropriate treatment regime at the earliest possible phase would help to improve outcomes. Here we describe an automated microarray-based immunoassay using the Fraunhofer lab-on-a-chip platform for analysis of C-reactive protein due to its role in the hyper-inflammatory response.

Keywords: Biomarker; COVID-19; Cytokine storm; LOC; Lab-on-a-chip; SARS-CoV-2.

MeSH terms

COVID-19* / diagnosis
Cytokines / metabolism
Humans
Immunoassay
Lab-On-A-Chip Devices
SARS-CoV-2

Substances

Cytokines